Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986368 for Multiple Sclerosis Spasticity
NCT06782490Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Jun 2025
- Primary completion
- May 2027
- Countries
- 7
01
Overview
A Phase 2 trial of bms-986368 in multiple sclerosis (MS), sponsored by Celgene Corporation. Started Jun 2025; status: recruiting.
02
Drugs
bms-986368
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06782490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782490.